PMID- 37261136
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230704
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Apr
TI  - Adverse Events Reported From Hyaluronic Acid Dermal Filler Injections to the 
      Facial Region: A Systematic Review and Meta-Analysis.
PG  - e38286
LID - 10.7759/cureus.38286 [doi]
LID - e38286
AB  - Dermal filler injections are one of the most popular cosmetic procedures in the 
      United States. Of the many options available, hyaluronic acid (HA) dermal fillers 
      like Juvederm or Restylane are often used. Despite their use and popularity, 
      adverse events are known to occur from these procedures. Although most outcomes 
      may be mild and resolve over time, rare instances of severe complications cannot 
      be ignored, as these effects may be irreversible. Healthcare practitioners and 
      patients must be aware of these risks, as these cosmetic procedures can affect 
      the patient's quality of life. The aim of this study was to evaluate the 
      incidence of adverse events (AEs) reported from the use of hyaluronic acid dermal 
      fillers in the facial region. A systemized search of randomized controlled trials 
      was conducted using Cochrane Central, Embase, Medical Literature Analysis and 
      Retrieval System Online (MEDLINE), and the Web of Science databases. After 
      screening for eligibility and conducting a critical appraisal of the articles, 19 
      studies were retained for the final review. The meta-analysis results included 
      different side effects by facial location, i.e., nasolabial fold (NLF) vs. other 
      (midface, perioral line, and lip region). The midface includes the anteromedial 
      cheek region, the zygomaticomalar region, and the submalar region. The adverse 
      events were swelling, pain, erythema, bruising, lumps and bumps, firmness, 
      tenderness, itching, and skin discoloration. A significant difference was found 
      in the proportion of individuals experiencing swelling, lumps or bumps, and 
      firmness at the nasolabial fold site versus the midface, perioral line, and 
      lip region. There was no significant difference in the proportion of individuals 
      experiencing pain, erythema, bruising, tenderness, itching, or skin discoloration 
      at the nasolabial fold site versus the other sites. The study highlights the 
      prevalence of common AEs that can result from HA dermal fillers like Juvederm or 
      Restylane, thus emphasizing the importance of healthcare professionals explaining 
      the risk and benefits to patients.
CI  - Copyright (c) 2023, Colon et al.
FAU - Colon, Jessica
AU  - Colon J
AD  - Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 
      Fort Lauderdale, USA.
FAU - Mirkin, Sophia
AU  - Mirkin S
AD  - Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 
      Fort Lauderdale, USA.
FAU - Hardigan, Patrick
AU  - Hardigan P
AD  - Health Professions Division, Nova Southeastern University, Dr. Kiran C. Patel 
      College of Allopathic Medicine, Fort Lauderdale, Fl, USA.
FAU - Elias, Matthew J
AU  - Elias MJ
AD  - Dermatology, Elias Dermatology, LLC, Fort Lauderdale, USA.
FAU - Jacobs, Robin J
AU  - Jacobs RJ
AD  - Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, 
      Fort Lauderdale, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230429
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
EIN - Cureus. 2023 Jun 30;15(6):c125. PMID: 37397650
PMC - PMC10226824
OTO - NOTNLM
OT  - adverse events
OT  - cosmetic procedures
OT  - dermal fillers
OT  - facial region
OT  - hyaluronic acid
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2023/06/01 13:09
MHDA- 2023/06/01 13:10
PMCR- 2023/04/29
CRDT- 2023/06/01 10:36
PHST- 2023/03/30 00:00 [received]
PHST- 2023/04/25 00:00 [accepted]
PHST- 2023/06/01 13:10 [medline]
PHST- 2023/06/01 13:09 [pubmed]
PHST- 2023/06/01 10:36 [entrez]
PHST- 2023/04/29 00:00 [pmc-release]
AID - 10.7759/cureus.38286 [doi]
PST - epublish
SO  - Cureus. 2023 Apr 29;15(4):e38286. doi: 10.7759/cureus.38286. eCollection 2023 
      Apr.